文献速递药物不良反应与药物警戒特殊人群用药

全基因组关联研究识别与药物相关性颌骨坏死相关的8号染色体位点

Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw.
PubMed 文献 · Clin Pharmacol Ther · 2021-08-31

该研究对5,008名接受双膦酸盐治疗的欧洲裔个体(含444例MRONJ病例和4,564例对照)进行GWAS荟萃分析,发现8号染色体rs2736308与MRONJ风险增加相关(癌症患者荟萃分析OR=2.71,95%CI 1.90-3.86,P=3.57*10-8),并在骨质疏松患者中验证(OR=2.82,95%CI 1.55-4.09,P=6.84*10-4),合并分析OR=2.74(95%CI 2.09-3.39,P=9.65*10-11),该位点调控BLK、CTSB和FDFT1基因。

要点

  • rs2736308与双膦酸盐相关MRONJ风险增加相关,合并OR=2.74。
  • 该位点调控BLK、CTSB和FDFT1基因,FDFT1参与双膦酸盐通路。
  • 研究为MRONJ的潜在机制提供线索,提示药物基因组学标志物。

核心结论

  • 8号染色体rs2736308与双膦酸盐治疗患者的MRONJ风险增加相关,合并OR=2.74(95%CI 2.09-3.39,P=9.65*10-11)。

研究设计与样本

  • 研究为GWAS荟萃分析,纳入5,008名接受双膦酸盐治疗的欧洲裔个体,含444例MRONJ病例和4,564例对照。
  • 发现阶段在随机选取的70%癌症患者中进行,复制阶段在剩余30%接受静脉双膦酸盐的癌症患者中进行,并对全部3,639例癌症患者进行荟萃分析。
  • 另在1,369例接受口服双膦酸盐的骨质疏松患者中进行了GWAS。

主要发现

  • 癌症患者荟萃分析中,rs2736308与MRONJ风险增加相关(OR=2.71,95%CI 1.90-3.86,P=3.57*10-8)。
  • 骨质疏松患者GWAS中该SNP得到验证(OR=2.82,95%CI 1.55-4.09,P=6.84*10-4)。
  • 癌症与骨质疏松患者合并荟萃分析显示同一lead SNP rs2736308为top SNP(OR=2.74,95%CI 2.09-3.39,P=9.65*10-11)。
  • 该位点与BLK、CTSB和FDFT1基因的调控相关,这些基因与骨密度相关;FDFT1编码的膜相关酶参与双膦酸盐通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious drug-related adverse event. To identify pharmacogenomic markers of MRONJ associated with bisphosphonate therapy, we conducted a genomewide association study (GWAS) meta-analysis followed by functional analysis of 5,008 individuals of European ancestry treated with bisphosphonates, which includes the largest number of MRONJ cases to date (444 cases and 4,564 controls). Discovery GWAS was performed in randomly selected 70% of the patients with cancer and replication GWAS was performed in the remaining 30% of the patients with cancer treated with intravenous bisphosphonates followed by meta-analysis of all 3,639 patients with cancer. GWAS was also performed in 1,369 patients with osteoporosis treated with oral bisphosphonates. The lead single-nucleotide polymorphism (SNP), rs2736308 on chromosome 8, was associated with an increased risk of MRONJ with an odds ratio (OR) of 2.71 and 95% confidence interval (CI) of 1.90-3.86 (P = 3.57*10-8 ) in the meta-analysis of patients with cancer. This SNP was validated in the MRONJ GWAS in patients with osteoporosis (OR: 2.82, 95% CI: 1.55-4.09, P = 6.84*10-4 ). The meta-analysis combining patients with cancer and patients with osteoporosis yielded the same lead SNP rs2736308 on chromosome 8 as the top SNP (OR: 2.74, 95% CI: 2.09-3.39, P = 9.65*10-11 ). This locus is associated with regulation of the BLK, CTSB, and FDFT1 genes, which had been associated with bone mineral density. FDFT1 encodes a membrane-associated enzyme, which is implicated in the bisphosphonate pathway. This study provides insights into the potential mechanism of MRONJ.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yang G, Singh S, McDonough CW, et al. Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. Clin Pharmacol Ther. 2021. PMID: 34390503. doi:10.1002/cpt.2397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。